Medication info
Linagliptin Plus XR Tablet 5/1000 mg (Linagliptin, Metformin Hydrochloride)

Linagliptin Plus XR Tablet 5/1000 mg (Linagliptin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Linagliptin Micronized›5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Jeil Pharmaceutical Co., Ltd.
Appearance
White oval extended-release film-coated tablet
Packaging
Bottle - 30 tablets/bottle, Bottle - 100 tablets/bottle
Approval status
Active

MFDS item code 202400187 · Approved 2024.01.24 · Insurance code 645406390

Summary

Main use
Improves blood glucose control in type 2 diabetes
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg. This drug should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, this drug must be swallowed whole without splitting, crushing, grinding, or chewing. Take 1 tablet of this drug 5/1000 mg extended-release tablet once daily. Patients taking this drug 2.5/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently treated with metformin: The initial dose of this drug is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. Patients treated with metformin - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the initial dose of this drug is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this drug similar to the patient's current dose of metformin hydrochloride, together with a total daily dose of linagliptin 5mg, should be considered. When this drug is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from immediate-release metformin to an extended-release formulation, blood glucose control should be closely monitored and the dose adjusted as appropriate if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this drug, the dose of this drug should be equivalent to the patient's current doses of linagliptin and extended-release metformin hydrochloride. Renal impairment Because dose adjustment according to renal function is required, assessment of renal function is recommended before starting this drug and periodically thereafter. No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A) whose creatinine clearance (CrCl) is ≥ 45mL/min and < 60mL/min or whose estimated glomerular filtration rate (eGFR) is ≥ 45mL/min/1.73m2 and < 60mL/min/1.73m2, this drug may be used with metformin hydrochloride dose adjustment as described below, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to < 45mL/min or estimated glomerular filtration rate (eGFR) decreases to < 45mL/min/1.73m2, this drug should be discontinued immediately.

Ingredients

Manufacturer
Jeil Pharmaceutical Co., Ltd.

Efficacy & effects

Improves blood glucose control in type 2 diabetes

View approved original text

This medication is used in conjunction with diet and exercise to help control blood sugar in patients with type 2 diabetes. It helps maintain effective blood sugar levels through a combination of linagliptin and metformin, thereby improving blood sugar levels and contributing to diabetes management.

How to take

Adult dose

In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg. This drug should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, this drug must be swallowed whole without splitting, crushing, grinding, or chewing. Take 1 tablet of this drug 5/1000 mg extended-release tablet once daily. Patients taking this drug 2.5/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently treated with metformin: The initial dose of this drug is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. Patients treated with metformin - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the initial dose of this drug is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this drug similar to the patient's current dose of metformin hydrochloride, together with a total daily dose of linagliptin 5mg, should be considered. When this drug is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from immediate-release metformin to an extended-release formulation, blood glucose control should be closely monitored and the dose adjusted as appropriate if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this drug, the dose of this drug should be equivalent to the patient's current doses of linagliptin and extended-release metformin hydrochloride. Renal impairment Because dose adjustment according to renal function is required, assessment of renal function is recommended before starting this drug and periodically thereafter. No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A) whose creatinine clearance (CrCl) is ≥ 45mL/min and < 60mL/min or whose estimated glomerular filtration rate (eGFR) is ≥ 45mL/min/1.73m2 and < 60mL/min/1.73m2, this drug may be used with metformin hydrochloride dose adjustment as described below, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to < 45mL/min or estimated glomerular filtration rate (eGFR) decreases to < 45mL/min/1.73m2, this drug should be discontinued immediately.

Precautions

This medication is primarily used to treat diabetes and helps control blood sugar levels. Rarely, while taking this medication, a serious condition called lactic acidosis may occur, which can happen when lactic acid accumulates excessively in the body and can be dangerous, so caution is needed. It is generally unsafe for patients with severely decreased kidney function, poor liver function, acute infections, or dehydration to take this medication. Pregnant women or patients with serious heart conditions are also advised against using this medication. This medication can cause hypoglycemia, so when taken together with other blood sugar-lowering agents such as insulin or sulfonylureas, blood sugar levels should be monitored regularly. Symptoms such as gastrointestinal disturbances, abdominal pain, diarrhea, nausea, and vomiting may occur during treatment, though these usually improve over time. Acute pancreatitis or skin blistering conditions may occur, so if severe abdominal pain or skin rashes develop, it is important to consult a doctor immediately. Vitamin B12 levels may decrease, so if taken for an extended period, regular blood tests to monitor this are necessary. This medication should be swallowed whole without breaking, crushing, or chewing the tablet; the coating may appear in stool, but this is normal. There may be interactions with other medications, so always inform your doctor or pharmacist of other medications you are taking. Particularly when used with medications that may affect kidney function, kidney function should be monitored closely. When undergoing examinations with contrast media, this medication should be discontinued for a certain period before and after the examination and resumed only after kidney function has stabilized. Because elderly patients may have decreased kidney function, dose adjustments and regular kidney function tests are required. Women who are pregnant or breastfeeding should avoid using this medication, and if planning to become pregnant, they should consult with a doctor. In the case of an overdose, gastrointestinal disturbances or lactic acidosis may occur, so if suspected, seek medical attention immediately. When storing this medication, keep it out of reach of children, avoid moisture, and store it in its original container.

Side effects

  • Severe lactic acidosis
  • hypoglycemia
  • angioedema
  • urticaria
  • lactic acidosis
  • abnormal vitamin B12 absorption test
  • hypoglycemic episode
  • taste disturbance
  • cough
  • decreased appetite
Show 131 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer
  • abnormal liver function test
  • hepatitis
  • itching
  • erythema
  • rash
  • pemphigus-like lesions
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • nasopharyngitis
  • hypersensitivity
  • constipation
  • upper abdominal pain
  • enterocolitis
  • bowel obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • reduced appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • stuttering
  • Alzheimer's type dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot disease
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscal injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • anxiety
  • mood disorders
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • chest discomfort
  • asthenia
  • pain
  • epistaxis
  • oropharyngeal pain
  • speech disturbance
  • allergic rhinitis
  • exercise-induced dyspnea
  • wet cough
  • rhinorrhea
  • pulmonary mass
  • arthralgia
  • osteoporosis
  • arthropathy
  • musculoskeletal discomfort
  • myositis
  • myalgia
  • soft tissue mass
  • postmenopausal osteoporosis
  • rotator cuff syndrome
  • increased serum triglycerides
  • increased urine albumin/creatinine ratio
  • positive urine leukocytes
  • reduced hemoglobin
  • increased serum potassium
  • increased serum creatinine
  • increased serum creatine phosphokinase
  • increased ALT
  • male pattern baldness
  • hyperhidrosis
  • dermatitis
  • goiter
  • confusion state
  • nocturia
  • dermatitis
  • hypertension
  • hearing loss
  • erectile dysfunction
  • benign prostatic hyperplasia
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • gingivitis
  • dyspepsia
  • rectal bleeding
  • cheilitis
  • dental caries
  • enteritis
  • gastritis
  • oral mucositis
  • increased serum creatinine

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture and should be stored in a tightly sealed container. It is best to maintain the storage temperature between 1 degree and 30 degrees Celsius. Proper storage helps maintain the medication's effectiveness over time.

Appearance and packaging

Appearance

White oval extended-release film-coated tablet

Package unit

Bottle - 30 tablets/bottle, Bottle - 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.